Video: In vivo efficacy of the recombinant influenza vaccine candidate CiFlu derived from the CIBEX system

On September 3, 2022 Cilian presented at the 8th International Influenza Meeting in Muenster. Dr. Marcus Hartmann, Founder and CSO of Cilian, presented the unique qualities and capabilities of Cilian’s proprietary CIBEX protein expression system; and data showing the development of an effective, fully recombinant, non-egg-based subunit influenza vaccine candidate. Development data from in-vivo studies has also been peer reviewed and published in Frontiers of Immunology.